Where does RNAZ stock trade?

TransCode Therapeutics Inc. (RNAZ) is listed on NASDAQ.

What sector and industry is RNAZ in?

TransCode Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.

When did TransCode Therapeutics Inc. go public?

TransCode Therapeutics Inc. (RNAZ) completed its IPO in 2021.

What companies are similar to RNAZ?

Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare RNAZ side-by-side with any of them on Quantisnow.

How can I track RNAZ on Quantisnow?

Quantisnow aggregates TransCode Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RNAZ to receive live email and push alerts on every new disclosure.

RNAZ

NASDAQ

TransCode Therapeutics Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2021

$4.68-1.00 (-17.61%)

News25/Ratings0

Price$4.68-0.86 (-15.45%)

03:15 PM07:15 PM

News · 26 weeks39+83%

2025-12-142026-06-07

Mix2290d

SEC Filings15(68%)
Other6(27%)
Leadership1(5%)

Latest news

25 items

17hPR
TransCode Therapeutics to Host R&D Webcast on June 18, 2026
Live Webcast to Highlight TTX-MC138 Phase 2a Trial, Three-Platform Pipeline, and Investment ThesisBOSTON, June 8, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical-stage oncology company advancing a three-platform pipeline in RNA therapeutics and immuno-oncology, today announced it will host its first live virtual R&D Webcast on Thursday, June 18, 2026, at 10:00 a.m. Eastern Time. The webcast will provide strategic, scientific, and clinical program updates anchored by TransCode's recently-initiated Phase 2a clinical trial of TTX-MC138 — the Company's lead antagomiR program — in ctDNA-positive colorecta
5dSEC
TransCode Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)
5dPR
TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer
TransCode reports no dose-limiting toxicities, durable disease stabilization in metastatic patients; advances to Phase 2 development in ctDNA-positive cancers using next-generation RNA therapeutics.BOSTON, June 3, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ) a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced further results of the Phase 1a dose escalation clinical trial. The trial met its primary endpoint of safety, with positive tolerability, combined with disease stabilization in multiple patients, and the absence of dose-limiting toxicities with its lead therapeutic candidate TTX-MC138. TTX-MC1
6dSEC
SEC Form DEF 14A filed by TransCode Therapeutics Inc.
DEF 14A - Transcode Therapeutics, Inc. (0001829635) (Filer)
7dSEC
TransCode Therapeutics Inc. filed SEC Form 8-K: Shareholder Director Nominations
8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)
12dPR
TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer
BOSTON, May 27, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced the initiation of its Phase 2a clinical trial. The study is to evaluate TransCode's lead therapeutic candidate, TTX‑MC138, in patients with circulating tumor DNA (ctDNA) positive colorectal cancer following curative‑intent therapy. The trial is being conducted in collaboration with Quantum Leap Healthcare Collaborative (QLHC), sponsor of the PRE‑I‑SPY clinical trial platform. The trial builds on growing clinical and scientific momentum supporting ctDNA‑guided strategies targeting minima
13dSEC
SEC Form DEFA14A filed by TransCode Therapeutics Inc.
DEFA14A - Transcode Therapeutics, Inc. (0001829635) (Filer)
13dSEC
Amendment: TransCode Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
8-K/A - Transcode Therapeutics, Inc. (0001829635) (Filer)
17dSEC
TransCode Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)
20dSEC
SEC Form EFFECT filed by TransCode Therapeutics Inc.
EFFECT - Transcode Therapeutics, Inc. (0001829635) (Filer)
20dSEC
SEC Form EFFECT filed by TransCode Therapeutics Inc.
EFFECT - Transcode Therapeutics, Inc. (0001829635) (Filer)
24dSEC
SEC Form 10-Q filed by TransCode Therapeutics Inc.
10-Q - Transcode Therapeutics, Inc. (0001829635) (Filer)
31dSEC
SEC Form PRE 14A filed by TransCode Therapeutics Inc.
PRE 14A - Transcode Therapeutics, Inc. (0001829635) (Filer)
39dSEC
SEC Form S-3 filed by TransCode Therapeutics Inc.
S-3 - Transcode Therapeutics, Inc. (0001829635) (Filer)
39dSEC
Amendment: SEC Form 10-K/A filed by TransCode Therapeutics Inc.
10-K/A - Transcode Therapeutics, Inc. (0001829635) (Filer)
42dPR
TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University
BOSTON, April 27, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering RNA and immuno-oncology therapeutics for the treatment of high risk and advanced cancers, today announced the appointment of Anna Moore, PhD, as Chair of its Scientific Advisory Board and the signing of a sponsored research agreement (SRA) with Michigan State University (MSU). Dr. Moore, Associate Dean for Research Development, Director of the Precision Health Program and Professor in the Departments of Radiology and Physiology at Michigan State University, is a
49dSEC
SEC Form SCHEDULE 13G filed by TransCode Therapeutics Inc.
SCHEDULE 13G - Transcode Therapeutics, Inc. (0001829635) (Subject)
54dSEC
SEC Form 10-K filed by TransCode Therapeutics Inc.
10-K - Transcode Therapeutics, Inc. (0001829635) (Filer)
62dSEC
SEC Form DEFA14A filed by TransCode Therapeutics Inc.
DEFA14A - Transcode Therapeutics, Inc. (0001829635) (Filer)
62dSEC
TransCode Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)
62dPR
TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028
BOSTON, April 7, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ, the ", Company", )), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced that it has entered into an agreement with an institutional healthcare investor for financing of up to $20 million. The arrangement comprises pre-paid advances of up to $6 million and a three-year Standby Equity Purchase Agreement (SEPA) providing the Company the right to sell up to $14 million of its common stock to the investor, subject to certain conditions.
69dSEC
SEC Form NT 10-K filed by TransCode Therapeutics Inc.
NT 10-K - Transcode Therapeutics, Inc. (0001829635) (Filer)
97dSEC
SEC Form DEFA14A filed by TransCode Therapeutics Inc.
DEFA14A - Transcode Therapeutics, Inc. (0001829635) (Filer)
97dSEC
TransCode Therapeutics Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)
97dPR
TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients
TransCode adds a unique adenovirus technology platform to its early-stage pipeline that has the potential to address a difficult to treat disease such as muscle-invasive bladder cancer.BOSTON, March 3, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced that it has entered into an exclusive, worldwide, fully paid-up royalty-free license agreement with Unleash Immuno Oncolytics, Inc. ("Unleash"). TransCode obtained the rights to develop three Unleash drug candidates, UIO-524, UIO-525 and UIO-526, which includes a license of all in-licensed rights held by

RNAZ FAQ

5 questions

Where does RNAZ stock trade?
TransCode Therapeutics Inc. (RNAZ) is listed on NASDAQ.
What sector and industry is RNAZ in?
TransCode Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
When did TransCode Therapeutics Inc. go public?
TransCode Therapeutics Inc. (RNAZ) completed its IPO in 2021.
What companies are similar to RNAZ?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare RNAZ side-by-side with any of them on Quantisnow.
How can I track RNAZ on Quantisnow?
Quantisnow aggregates TransCode Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RNAZ to receive live email and push alerts on every new disclosure.